# Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies

> **NCT05510089** · NA · UNKNOWN · sponsor: **The Affiliated People's Hospital of Ningbo University** · enrollment: 62 (estimated)

## Conditions studied

- Hematological Malignancy

## Interventions

- **DRUG:** Etoposide
- **DRUG:** Cytarabine
- **DRUG:** PEG-rhG-CSF

## Key facts

- **NCT ID:** NCT05510089
- **Lead sponsor:** The Affiliated People's Hospital of Ningbo University
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-01
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05510089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05510089, "Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT05510089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*